Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 39% ± 12% | |
lung | 18 studies | 26% ± 11% | |
brain | 13 studies | 33% ± 14% | |
intestine | 7 studies | 20% ± 5% | |
bone marrow | 4 studies | 34% ± 11% | |
uterus | 4 studies | 22% ± 8% | |
lymph node | 4 studies | 36% ± 5% | |
liver | 4 studies | 32% ± 11% | |
adipose | 4 studies | 25% ± 5% | |
pancreas | 3 studies | 34% ± 11% | |
placenta | 3 studies | 41% ± 15% | |
kidney | 3 studies | 27% ± 7% | |
breast | 3 studies | 19% ± 2% | |
heart | 3 studies | 16% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7615.94 | 1445 / 1445 | 100% | 83.00 | 183 / 183 |
intestine | 100% | 8805.74 | 966 / 966 | 100% | 105.47 | 527 / 527 |
prostate | 100% | 7072.08 | 245 / 245 | 100% | 106.95 | 502 / 502 |
stomach | 100% | 5501.28 | 359 / 359 | 100% | 96.47 | 286 / 286 |
brain | 100% | 8618.94 | 2640 / 2642 | 100% | 156.09 | 705 / 705 |
lung | 100% | 9248.30 | 578 / 578 | 100% | 125.39 | 1154 / 1155 |
breast | 100% | 6865.41 | 459 / 459 | 100% | 187.27 | 1117 / 1118 |
thymus | 100% | 5837.82 | 653 / 653 | 100% | 113.52 | 604 / 605 |
uterus | 100% | 7060.22 | 170 / 170 | 100% | 119.08 | 458 / 459 |
ovary | 100% | 5400.76 | 180 / 180 | 100% | 79.03 | 429 / 430 |
bladder | 100% | 7440.05 | 21 / 21 | 100% | 113.07 | 502 / 504 |
kidney | 100% | 6906.19 | 89 / 89 | 100% | 117.12 | 897 / 901 |
skin | 100% | 5916.72 | 1808 / 1809 | 100% | 134.17 | 470 / 472 |
liver | 100% | 4289.55 | 226 / 226 | 100% | 79.18 | 404 / 406 |
adrenal gland | 100% | 8691.57 | 258 / 258 | 99% | 99.35 | 227 / 230 |
pancreas | 98% | 2964.07 | 321 / 328 | 99% | 105.37 | 176 / 178 |
adipose | 100% | 7374.02 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 335.92 | 29 / 29 |
spleen | 100% | 14659.38 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 118.08 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 66.42 | 1 / 1 |
blood vessel | 100% | 7493.68 | 1334 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 20322.37 | 926 / 929 | 0% | 0 | 0 / 0 |
muscle | 100% | 3995.87 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 4898.42 | 850 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 69.93 | 78 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007265 | Biological process | Ras protein signal transduction |
GO_0030838 | Biological process | positive regulation of actin filament polymerization |
GO_0031623 | Biological process | receptor internalization |
GO_0042552 | Biological process | myelination |
GO_0048009 | Biological process | insulin-like growth factor receptor signaling pathway |
GO_0007165 | Biological process | signal transduction |
GO_0050853 | Biological process | B cell receptor signaling pathway |
GO_0035987 | Biological process | endodermal cell differentiation |
GO_0042267 | Biological process | natural killer cell mediated cytotoxicity |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0014044 | Biological process | Schwann cell development |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0060670 | Biological process | branching involved in labyrinthine layer morphogenesis |
GO_0007173 | Biological process | epidermal growth factor receptor signaling pathway |
GO_0043408 | Biological process | regulation of MAPK cascade |
GO_0071479 | Biological process | cellular response to ionizing radiation |
GO_0042770 | Biological process | signal transduction in response to DNA damage |
GO_0008543 | Biological process | fibroblast growth factor receptor signaling pathway |
GO_0005730 | Cellular component | nucleolus |
GO_0005886 | Cellular component | plasma membrane |
GO_0012506 | Cellular component | vesicle membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005911 | Cellular component | cell-cell junction |
GO_0070436 | Cellular component | Grb2-EGFR complex |
GO_0005829 | Cellular component | cytosol |
GO_0005938 | Cellular component | cell cortex |
GO_0008180 | Cellular component | COP9 signalosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0005768 | Cellular component | endosome |
GO_0005634 | Cellular component | nucleus |
GO_0046875 | Molecular function | ephrin receptor binding |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0005154 | Molecular function | epidermal growth factor receptor binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0043560 | Molecular function | insulin receptor substrate binding |
GO_0005068 | Molecular function | transmembrane receptor protein tyrosine kinase adaptor activity |
GO_0005091 | Molecular function | guanyl-nucleotide exchange factor adaptor activity |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0001784 | Molecular function | phosphotyrosine residue binding |
GO_0005168 | Molecular function | neurotrophin TRKA receptor binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | GRB2 |
Protein name | Growth factor receptor-bound protein 2 (Adapter protein GRB2) (Protein Ash) (SH2/SH3 adapter GRB2) Growth factor receptor-bound protein 2 (cDNA, FLJ96637, Homo sapiens growth factor receptor-bound protein 2 (GRB2), mRNA) GRB2 protein Growth factor receptor bound protein 2 |
Synonyms | ASH hCG_27179 |
Description | FUNCTION: Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway. .; FUNCTION: [Isoform 2]: Does not bind to phosphorylated epidermal growth factor receptor (EGFR) but inhibits EGF-induced transactivation of a RAS-responsive element. Acts as a dominant negative protein over GRB2 and by suppressing proliferative signals, may trigger active programmed cell death. . |
Accessions | J3QLF6 ENST00000581959.1 J3KT38 ENST00000392563.5 [P62993-2] ENST00000316615.9 [P62993-2] ENST00000582582.1 J3QRL5 ENST00000648046.1 [P62993-1] Q6ICN0 B0LPF3 P62993 ENST00000578961.5 ENST00000392564.5 [P62993-1] ENST00000316804.10 [P62993-1] ENST00000392562.5 [P62993-1] |